Zacks: Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) Receives Consensus Recommendation of “Strong Buy” from Analysts
Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) has been given an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus price target of $23.33 for the company and are expecting that the company will post ($0.65) EPS for the current quarter, according to Zacks. Zacks has also assigned Catabasis Pharmaceuticls an industry rank of 102 out of 265 based on the ratings given to related companies.
Several analysts have recently weighed in on CATB shares. Zacks Investment Research raised Catabasis Pharmaceuticls from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a report on Tuesday, July 5th. Cowen and Company reissued a “buy” rating on shares of Catabasis Pharmaceuticls in a report on Wednesday, June 8th. Oppenheimer Holdings Inc. reissued an “outperform” rating and issued a $28.00 target price on shares of Catabasis Pharmaceuticls in a report on Wednesday, May 25th. Finally, Wedbush reissued an “outperform” rating and issued a $17.00 target price on shares of Catabasis Pharmaceuticls in a report on Friday, August 12th.
Hedge funds have recently bought and sold shares of the stock. Bridgeway Capital Management Inc. bought a new stake in Catabasis Pharmaceuticls during the second quarter valued at approximately $102,000. Sphera Funds Management LTD. boosted its position in Catabasis Pharmaceuticls by 184.9% in the first quarter. Sphera Funds Management LTD. now owns 230,041 shares of the company’s stock valued at $1,159,000 after buying an additional 149,299 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB boosted its position in Catabasis Pharmaceuticls by 12.7% in the first quarter. Rhenman & Partners Asset Management AB now owns 345,100 shares of the company’s stock valued at $1,739,000 after buying an additional 38,873 shares during the last quarter. 66.58% of the stock is owned by hedge funds and other institutional investors.
Catabasis Pharmaceuticls (NASDAQ:CATB) opened at 4.4801 on Monday. The company’s market cap is $68.91 million. Catabasis Pharmaceuticls has a 52-week low of $3.31 and a 52-week high of $10.83. The stock’s 50 day moving average price is $4.71 and its 200 day moving average price is $4.86.
Catabasis Pharmaceuticls (NASDAQ:CATB) last posted its earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.04. Analysts expect that Catabasis Pharmaceuticls will post ($2.47) earnings per share for the current year.
About Catabasis Pharmaceuticls
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related companies with MarketBeat.com's FREE daily email newsletter.